Table 3.
The main pharmacokinetic parameters of the indicated preparations in male Wistar rats (n=6)
| Formulation of SM | Tmax (h) | Cmax (μg/mL) | AUC0−t (μg/mL h) |
|---|---|---|---|
| SM powder | 1.417±0.204 | 0.640±0.132 | 3.824±0.355 |
| Commercial product | 0.916±0.129 | 0.703±0.072 | 7.753±0.576* |
| SM-Lip-SEDS | 7.667±0.816* | 1.296±0.137* | 18.406±1.481* |
| SM-Lip-RPE | 5.667±0.816* | 1.162±0.103* | 15.331±2.181* |
| SM-Lip-TFD | 5.500±1.225* | 0.931±0.115* | 14.054±1.417* |
Note:
*
P<0.05, compared to the SM powder (conventional powder formulation).
Abbreviations: SM, silymarin; h, hour; Lip, liposomes; SEDS, solution-enhanced dispersion by supercritical fluids; RPE, reversed-phase evaporation; Tmax, time peak plasma concentration; Cmax, peak plasma concentration; AUC0−t, area under the plasma concentration-time curve; TFD, thin-film dispersion.